Leading Eye Institute to Participate in ACT's Embryonic Stem Cell Clinical Trial for Macular Degeneration Wills Eye Institute receives IRB approval to treat dry-AMD using ACT's hESC-derived retinal pigment epithelial (RPE) cells

Document Type

Popular Press

Publication Date



Press release announcing:

MARLBOROUGH, Mass., Jan 17, 2012 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), a leader in the field of regenerative medicine, today announced that the Wills Eye Institute in Philadelphia has received institutional review board (IRB) approval as a site for the Phase 1/2 clinical trial for dry age-related macular degeneration (dry AMD) using human embryonic stem cell (hESC)-derived retinal pigment epithelial (RPE) cells.